

CCS/CHFS Heart Failure Guidelines Update: Defining a for Heart Failure With Reduced Ejection Fraction

Canadian Journal of Cardiology

37, 531-546

DOI: [10.1016/j.cjca.2021.01.017](https://doi.org/10.1016/j.cjca.2021.01.017)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology, 2021, 37, 632-643.	0.8	31
2	Timely and individualized heart failure management: need for implementation into the new guidelines. Clinical Research in Cardiology, 2021, 110, 1150-1158.	1.5	18
3	From Editor-in-Chief: On current issue, important cardiovascular documents and trials, COVID-19 sequelae, and welcome to a new Editor. Heart Vessels and Transplantation, 0, 5, .	0.0	0
4	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Current Opinion in Cardiology, 2021, 36, 672-681.	0.8	9
5	Juggling While Dancing. JACC: Case Reports, 2021, 3, 1077-1080.	0.3	0
6	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	9
7	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. Revista Portuguesa De Cardiologia, 2021, 40, 975-983.	0.2	6
8	The Use of β -Blockers in Heart Failure with Reduced Ejection Fraction. Journal of Cardiovascular Development and Disease, 2021, 8, 101.	0.8	14
9	Residuals. Circulation, 2021, 144, 438-440.	1.6	1
10	Tailored use of β blockers using artificial intelligence. Lancet, The, 2021, 398, 1385-1386.	6.3	2
11	Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis. CJC Open, 2021, 3, S202-S208.	0.7	8
12	Does Anyone Read Heart Failure Guidelines? Why You Should Read the Japanese Guideline!. Journal of Cardiac Failure, 2021, 27, 1445-1446.	0.7	0
13	Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?. Frontiers in Cardiovascular Medicine, 2021, 8, 744243.	1.1	4
14	Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications. Journal for Nurse Practitioners, 2021, , .	0.4	0
15	Cardiac Sarcoidosis: A Clinical Overview. Current Problems in Cardiology, 2021, 46, 100936.	1.1	3
16	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism: Clinical and Experimental, 2022, 126, 154918.	1.5	42
17	Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 655-663.	0.7	7
18	Universal Definition and Classification of Heart Failure: Pharmacists's Perspective: Optimizing Guideline-Directed Medical Therapy and Educating Stakeholders. Journal of Cardiac Failure, 2021, 27, 1310-1312.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2013-2016.	1.2	1
20	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Frontiers in Cardiovascular Medicine, 2021, 8, 754499.	1.1	30
21	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	0.7	4
22	Cardiovascular benefit of SGLT2 inhibitors. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 142-155.	2.7	6
23	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical Drug Investigation, 2022, 42, 1-16.	1.1	4
24	Efficacy and Safety of Traditional Chinese Medicine Injections for Heart Failure With Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2021, 12, 659707.	1.6	6
25	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
26	Avoidance of β -blockers in patients who use stimulants is not supported by good evidence. Cmaj, 2022, 194, E127-E128.	0.9	2
28	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 132-142.	2.9	30
29	Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2022, 17, e0263131.	1.1	15
30	Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy. Scientific Reports, 2022, 12, 1739.	1.6	5
31	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs, 2022, 82, 375-405.	4.9	7
32	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 2022, 79, 504-510.	1.2	21
33	Drug therapy for heart failure with reduced ejection fraction: what is the "right" dose?. European Journal of Heart Failure, 2022, 24, 421-430.	2.9	9
34	Nueva guía de insuficiencia cardiaca de la HFA-ESC 2021. Un enfoque práctico e integral. Revista Española De Cardiología, 2022, , .	0.6	1
35	A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. European Heart Journal, 2022, 43, 2562-2569.	1.0	39
37	Cluster Scheme Approach to Foundational Heart Failure With Reduced Ejection Fraction Therapy. Journal for Nurse Practitioners, 2022, , .	0.4	0
38	New 2021 ESC/HFA heart failure guidelines. A practical comprehensive approach. Revista Española De Cardiología (English Ed), 2022, 75, 548-548.	0.4	3

#	ARTICLE	IF	CITATIONS
39	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
40	Optimizing Foundational Therapies in Patients With HFrEF. <i>JACC Basic To Translational Science</i> , 2022, 7, 504-517.	1.9	47
42	Fluid Restriction: Time to Let it Flow?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1480-1481.	0.7	3
43	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet</i> , The, 2022, 399, 1391-1400.	6.3	67
45	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement. <i>Heart Rhythm O2</i> , 2021, 2, 698-709.	0.6	4
46	A year in heart failure: an update of recent findings. <i>ESC Heart Failure</i> , 2021, 8, 4370-4393.	1.4	28
47	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 975-983.	0.2	0
48	Rapid Sequencing of Foundational Treatment for HFrEF: The Innovative Proposal of John McMurray and Milton Packer. , 2022, 2, 27-30.		0
49	The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women Chapter 6: Sex- and Gender-Specific Diagnosis and Treatment. <i>CJC Open</i> , 2022, 4, 589-608.	0.7	13
50	What's all the fuss about a new guideline?. <i>European Journal of Heart Failure</i> , 2022, 24, 743-745.	2.9	0
51	Sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. <i>Canadian Family Physician</i> , 2021, 67, 678-678.	0.1	0
53	Medication management for heart failure with reduced ejection fraction. <i>Canadian Family Physician</i> , 2021, 67, 915-922.	0.1	1
57	Transcatheter Edge-to-Edge Mitral Valve Repair in Functional Mitral Regurgitation. Does it Pass Muster? Still Leaving Plenty to Be Desired. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2022, 37, I-IV.	0.2	0
59	Vericiguat in heart failure: From scientific evidence to clinical practice. <i>Revista Colombiana Espanola</i> , 2022, 222, 359-369.	0.3	5
60	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
61	Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 451-459.	1.0	8
62	Current Emergency Department Disposition of Patients With Acute Heart Failure: An Opportunity for Improvement. <i>Journal of Cardiac Failure</i> , 2022, 28, 1545-1559.	0.7	5
63	Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. <i>American Heart Journal</i> , 2022, 251, 127-136.	1.2	5

#	ARTICLE	IF	CITATIONS
64	Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. <i>Diabetes Therapy</i> , 2022, 13, 19-34.	1.2	3
65	Time to Revisit Heart Failure Self-Care. <i>Advances in Nursing Science</i> , 2022, 45, 371-386.	0.6	0
66	Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2022, 24, 1625-1632.	2.9	10
67	Progress in the Treatment of Heart Failure with Decreased Ejection Volume by Sacubatrovalsartan. <i>Advances in Clinical Medicine</i> , 2022, 12, 6440-6443.	0.0	1
68	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	1.0	15
69	Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review. <i>CJC Open</i> , 2022, 4, 802-809.	0.7	2
70	Significant Improvement in Digoxin Immunoassays Over Four Decades: Newer Assays are Less Affected by Interferences. <i>Therapeutic Drug Monitoring</i> , 2023, 45, 26-34.	1.0	1
71	Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
72	Evaluation of Online Written Medication Educational Resources for People Living With Heart Failure. <i>CJC Open</i> , 2022, 4, 858-865.	0.7	2
74	Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization. <i>Pharmacy Practice</i> , 2022, 20, 01-08.	0.8	0
76	Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
77	Use of Guideline-Directed Medical Therapy in Patients Aged ≥ 65 Years After the Diagnosis of Heart Failure: A Canadian Population-Based Study. <i>CJC Open</i> , 2022, 4, 1015-1023.	0.7	11
78	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. <i>CJC Open</i> , 2022, 4, 959-969.	0.7	3
79	Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1589-1599.	0.9	5
80	Current and future use of neuromodulation in heart failure. <i>European Heart Journal Supplements</i> , 2022, 24, E28-E34.	0.0	10
81	Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
82	Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1673-1682.	0.7	1
83	Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. <i>JACC: Heart Failure</i> , 2022, 10, 976-988.	1.9	3

#	ARTICLE	IF	CITATIONS
84	Multidisciplinary Heart Failure Care Program: An Experience From Colombia. <i>Current Problems in Cardiology</i> , 2023, 48, 101431.	1.1	1
85	Rapid recommendations. <i>Canadian Family Physician</i> , 2022, 68, 664-666.	0.1	1
86	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i> 2022, 64, 441-454.	0.1	0
87	Multi-omic biomarker approach to predict survival and adverse cardiovascular events among patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 1879-1882.	2.9	2
88	Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis. <i>Current Problems in Cardiology</i> , 2023, 48, 101412.	1.1	2
90	Use of Sacubitril/Valsartan Prior to Primary Prevention Implantable Cardioverter Defibrillator Implantation. <i>CJC Open</i> , 2022, , .	0.7	0
91	Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1529-1541.	1.2	13
92	Defining the gap in heart failure treatment in patients with cardiac implantable electronic devices. <i>Clinical Research in Cardiology</i> , 0, , .	1.5	3
93	Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021). <i>Canadian Journal of Diabetes</i> , 2023, 47, 153-161.	0.4	1
94	Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update. <i>Cmaj</i> , 2022, 194, E1460-E1480.	0.9	5
95	Polypharmacy and risk of mortality among patients with heart failure following hospitalization: a nested case-control study. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
96	Decisional Needs and Patient Treatment Preferences for Heart Failure Medications: A Scoping Review. <i>CJC Open</i> , 2023, 5, 136-147.	0.7	2
97	Should Catheter Ablation for Atrial Fibrillation be a Priority in Patients with Heart Failure with Reduced Ejection Fraction?. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2022, 8, 20.	0.2	0
98	Secular trends in the utility of SGLT2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland. <i>Internal Medicine Journal</i> , 0, , .	0.5	0
100	Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. <i>European Heart Journal Supplements</i> , 2022, 24, L20-L28.	0.0	7
101	Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. <i>Journal of Cardiac Failure</i> , 2023, 29, 389-402.	0.7	5
102	Management, clinical outcomes, and its predictors among heart failure patients admitted to tertiary care hospitals in Ethiopia: prospective observational study. <i>BMC Cardiovascular Disorders</i> , 2023, 23, .	0.7	2
103	Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. <i>CJC Open</i> , 2023, , .	0.7	0

#	ARTICLE	IF	CITATIONS
104	Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2023, 11, 596-606.	1.9	4
105	Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1
106	Effectiveness of mobile telemonitoring applications in heart failure patients: systematic review of literature and meta-analysis. <i>Heart Failure Reviews</i> , 0, , .	1.7	1
107	Ligne directrice C-CHANGE pour l'harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022. <i>Cmaj</i> , 2023, 195, E21-E42.	0.9	1
108	The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure. <i>Özget Baysal Türkiye Fakültesi Dergisi</i> , 2022, 11, 337-336.	0.0	2
109	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. <i>Canadian Journal of Kidney Health and Disease</i> , 2023, 10, 205435812211505.	0.6	3
110	Management of Heart Failure With Reduced Ejection Fraction. <i>Current Problems in Cardiology</i> , 2023, 48, 101596.	1.1	5
111	II. Details: Therapeutic Agents for Chronic Heart Failure; 2. SGLT2 Inhibitor. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2022, 111, 228-234.	0.0	0
112	Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2023, 376, 83-89.	0.8	8
113	Novel Treatments of Hypertrophic Cardiomyopathy in GDMT for Heart Failure: A State-of-art Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101740.	1.1	0
114	Development and Contribution of a Serious Game to Improve Nursing Students' Clinical Reasoning in Acute Heart Failure: A Multimethod Study. <i>CIN - Computers Informatics Nursing</i> , 0, Publish Ahead of Print, .	0.3	0
115	Time to Triple Therapy in Patients With de Novo Heart Failure With Reduced Ejection Fraction: a Population-Based Study. <i>Journal of Cardiac Failure</i> , 2023, 29, 719-729.	0.7	2
116	Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. <i>Heart</i> , 0, , heartjnl-2022-321702.	1.2	3
117	SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. <i>Medicina (Lithuania)</i> , 2023, 59, 388.	0.8	4
118	Personalized care of patients with heart failure: are we ready for a REWOLUTION ? Insights from two international surveys on healthcare professionals' needs and patients' perceptions. <i>European Journal of Heart Failure</i> , 2023, 25, 364-372.	2.9	3
119	Vericiguat for the treatment of heart failure with reduced ejection fraction. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 245-257.	0.6	1
120	Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?. <i>Canadian Journal of Cardiology</i> , 2023, , .	0.8	0
121	Identifying the patient with heart failure to be treated with vericiguat. <i>Current Medical Research and Opinion</i> , 2023, 39, 661-669.	0.9	1

#	ARTICLE	IF	CITATIONS
122	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	0.8	0
123	Quality improvement initiative to optimize heart failure treatment in patients with cardiac implantable electronic devices. Heart Rhythm O2, 2023, , .	0.6	0
124	Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat. Patient Preference and Adherence, 0, Volume 17, 839-849.	0.8	0
125	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. World Journal of Cardiovascular Diseases, 2023, 13, 138-169.	0.0	0
126	Heart failure: pathophysiology and the emergence of novel therapies. , 2023, , 441-458.		0
127	Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?. Current Heart Failure Reports, 0, , .	1.3	0
128	Person-Centered Cardiology. , 2023, , 501-538.		0
129	Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovascular Diabetology, 2023, 22, .	2.7	18
148	Obesity as a risk factor in atrial fibrillation and heart failure. Journal of Diabetes and Metabolic Disorders, 0, , .	0.8	1
153	The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
155	Cardiovascular Adverse Effects of Breast Cancer Chemotherapy. , 2023, , 233-243.		0
168	Survival Prediction of Heart Failure Patients Based on a Novel Decision Tree Model. , 2023, , .		0